Review





Similar Products

96
Selleck Chemicals nec
Nec, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nec/Nec-1s/pmc13755424-391-18-21
Average 96 stars, based on 1 article reviews
nec - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
MedChemExpress nec 1
Nec 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nec/Necrostatin-1/pm42954354-86-5-10
Average 99 stars, based on 1 article reviews
nec 1 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

96
Selleck Chemicals necrostatin 1s
Necrostatin 1s, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nec/Nec-1s/pm42880285-1412-37-39
Average 96 stars, based on 1 article reviews
necrostatin 1s - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
MedChemExpress nec
( A ) Volcano plot of differentially expressed genes (DEGs) in MFC cells (Control versus DDP + Zn 2+ ). ( B ) KEGG pathway enrichment of DEGs. ( C ) Quantification of extracellular dsDNA. ( D ) JC-1 staining assessed by fluorescence microscopy and flow cytometry. ( E ) γ-H2AX immunofluorescence staining. Scale bar, 20 μm. ( F ) ASC speck colocalization with AIM2, Caspase-1, Caspase-8, and RIPK1. Scale bars, 5 μm (overview) and 1 μm (enlarged). ( G ) Western blot analysis of necroptosis markers (RIPK1, p-RIPK1, MLKL, and p-MLKL) and PANoptosis-related proteins (AIM2 and ZBP1). ( H ) Western blot analysis of apoptosis executors (Caspase-8, Caspase-3, and cleaved forms). ( I ) Western blot analysis of pyroptosis markers (Caspase-1, GSDMD, and cleaved forms). ( J ) Cell viability after DDP + Zn 2+ combined with VX-765, Ac-DEVD-CHO, or <t>Nec-1.</t> ( K ) PANoptosis-related proteins in si AIM2 cells. ( L and M ) cGAS activity (L) and expression (M) under Zn 2+ treatment. ( N ) Violin plot of cGAS expression. ( O ) Western blot analysis of STING pathway (STING, p-STING, TBK1, p-TBK1, IRF3, and p-IRF3). ( P ) CIBERSORT analysis of immune cell infiltration. ( Q ) BMDC maturation (CD80 + CD86 + ) after different treatments. ( R ) Schematic of the DDP + Zn 2+ –induced ICD. Data in (C), (J), and (L) are mean ± SD. Statistical analysis for (C), (J), (L), (N), and (P) used a two-tailed unpaired Student’s t test. (R) was created in BioRender. Fei, G. (2026) https://BioRender.com/8ri399r . * P < 0.05.
Nec, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nec/Necrostatin-1/pmc13626044-427-6-10
Average 99 stars, based on 1 article reviews
nec - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

94
TargetMol necrosulfonamide nec
Combined drug treatment induces reactive oxygen species–mediated DNA damage and apoptosis. (A-D) Fluorescence images and statistical graphs depicting the alterations in reactive oxygen species (ROS) levels in DLD-1 and HCT116 cells, following a 1-hour exposure to four distinct drug administration protocols. Scale bars=100 µm. (E, F) Immunofluorescence images of DNA damage signs (γ-H2AX and 53BP1) in HCT116 cells after treatment. Scale bars=5 µm. (G) Comparative analysis of cell survival rates in colorectal cancer cells following treatment with pathway-specific inhibitors. (H-J) Expression levels and statistical analysis of Bcl-2 and Bax under various treatment conditions: dimethyl sulfoxide (DMSO), lenvatinib (LEN), celastrol (CELA), and the combined group. DFO, deferoxamine mesylate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; <t>NEC,</t> <t>necrosulfonamide;</t> Z-VAD, Z-VAD-FMK. Statistical significance was defined as * p < 0.05 and ** p < 0.01; ns, not significant.
Necrosulfonamide Nec, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nec/Necrosulfonamide/pmc13680069-36-3-12
Average 94 stars, based on 1 article reviews
necrosulfonamide nec - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology necrostatin 1 nec 1
Combined drug treatment induces reactive oxygen species–mediated DNA damage and apoptosis. (A-D) Fluorescence images and statistical graphs depicting the alterations in reactive oxygen species (ROS) levels in DLD-1 and HCT116 cells, following a 1-hour exposure to four distinct drug administration protocols. Scale bars=100 µm. (E, F) Immunofluorescence images of DNA damage signs (γ-H2AX and 53BP1) in HCT116 cells after treatment. Scale bars=5 µm. (G) Comparative analysis of cell survival rates in colorectal cancer cells following treatment with pathway-specific inhibitors. (H-J) Expression levels and statistical analysis of Bcl-2 and Bax under various treatment conditions: dimethyl sulfoxide (DMSO), lenvatinib (LEN), celastrol (CELA), and the combined group. DFO, deferoxamine mesylate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; <t>NEC,</t> <t>necrosulfonamide;</t> Z-VAD, Z-VAD-FMK. Statistical significance was defined as * p < 0.05 and ** p < 0.01; ns, not significant.
Necrostatin 1 Nec 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nec/Necrostatin-1/pm42816376-59-0-5
Average 93 stars, based on 1 article reviews
necrostatin 1 nec 1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

99
MedChemExpress necs
Combined drug treatment induces reactive oxygen species–mediated DNA damage and apoptosis. (A-D) Fluorescence images and statistical graphs depicting the alterations in reactive oxygen species (ROS) levels in DLD-1 and HCT116 cells, following a 1-hour exposure to four distinct drug administration protocols. Scale bars=100 µm. (E, F) Immunofluorescence images of DNA damage signs (γ-H2AX and 53BP1) in HCT116 cells after treatment. Scale bars=5 µm. (G) Comparative analysis of cell survival rates in colorectal cancer cells following treatment with pathway-specific inhibitors. (H-J) Expression levels and statistical analysis of Bcl-2 and Bax under various treatment conditions: dimethyl sulfoxide (DMSO), lenvatinib (LEN), celastrol (CELA), and the combined group. DFO, deferoxamine mesylate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; <t>NEC,</t> <t>necrosulfonamide;</t> Z-VAD, Z-VAD-FMK. Statistical significance was defined as * p < 0.05 and ** p < 0.01; ns, not significant.
Necs, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nec/BAY+11-7082/pm42784977-84-0-14
Average 99 stars, based on 1 article reviews
necs - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

96
TargetMol necrostatin 1 nec 1
HBT triggers PC9-OR cells ferroptosis. A Fer-1 treatment attenuated 2.5 μΜ HBT-caused inhibition effect on PC9-OR cell proliferation. The PC9-OR cells were co-treated with apoptosis inhibitor Z-VAD-FMK, ferroptosis inhibitor Fer-1, autophagy inhibitor CQ or necroptosis <t>inhibitor</t> <t>Nec-1</t> and HBT for 48 h, and then subjected for CCK-8 assay. B Fer-1 treatment weaken HBT-mediated PC9-OR cells death detected by Calcein-AM/PI staining assay. C HBT treatment induced intracellular ROS accumulation. D HBT treatment increased intracellular lipid peroxidation, as indicated by C11-BODIPY 581/591 staining assay. E HBT treatment increased intracellular Fe 2+ level. The PC9-OR cells were treated with various concentration of HBT for 12 h, and the Fe 2+ level were detected by flow cytometry. F , G HBT induced PC9-OR cells ferroptosis indicated by Western blotting assay. H HBT treatment induced mitochondrial morphology change. PC9-OR cells were treated with or without HBT for 24 h. And the subcellular organelle structure was observed using TME. All the data were presented as mean ± SD. n = 3. ** P < 0.01, *** P < 0.001 compared with the Vehicle group
Necrostatin 1 Nec 1, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nec/Necrostatin-1/pmc13569813-27-7-12
Average 96 stars, based on 1 article reviews
necrostatin 1 nec 1 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


( A ) Volcano plot of differentially expressed genes (DEGs) in MFC cells (Control versus DDP + Zn 2+ ). ( B ) KEGG pathway enrichment of DEGs. ( C ) Quantification of extracellular dsDNA. ( D ) JC-1 staining assessed by fluorescence microscopy and flow cytometry. ( E ) γ-H2AX immunofluorescence staining. Scale bar, 20 μm. ( F ) ASC speck colocalization with AIM2, Caspase-1, Caspase-8, and RIPK1. Scale bars, 5 μm (overview) and 1 μm (enlarged). ( G ) Western blot analysis of necroptosis markers (RIPK1, p-RIPK1, MLKL, and p-MLKL) and PANoptosis-related proteins (AIM2 and ZBP1). ( H ) Western blot analysis of apoptosis executors (Caspase-8, Caspase-3, and cleaved forms). ( I ) Western blot analysis of pyroptosis markers (Caspase-1, GSDMD, and cleaved forms). ( J ) Cell viability after DDP + Zn 2+ combined with VX-765, Ac-DEVD-CHO, or Nec-1. ( K ) PANoptosis-related proteins in si AIM2 cells. ( L and M ) cGAS activity (L) and expression (M) under Zn 2+ treatment. ( N ) Violin plot of cGAS expression. ( O ) Western blot analysis of STING pathway (STING, p-STING, TBK1, p-TBK1, IRF3, and p-IRF3). ( P ) CIBERSORT analysis of immune cell infiltration. ( Q ) BMDC maturation (CD80 + CD86 + ) after different treatments. ( R ) Schematic of the DDP + Zn 2+ –induced ICD. Data in (C), (J), and (L) are mean ± SD. Statistical analysis for (C), (J), (L), (N), and (P) used a two-tailed unpaired Student’s t test. (R) was created in BioRender. Fei, G. (2026) https://BioRender.com/8ri399r . * P < 0.05.

Journal: Science Advances

Article Title: Chemo-metallo nanodrivers for spatiotemporally controlled in situ vaccination

doi: 10.1126/sciadv.aee4577

Figure Lengend Snippet: ( A ) Volcano plot of differentially expressed genes (DEGs) in MFC cells (Control versus DDP + Zn 2+ ). ( B ) KEGG pathway enrichment of DEGs. ( C ) Quantification of extracellular dsDNA. ( D ) JC-1 staining assessed by fluorescence microscopy and flow cytometry. ( E ) γ-H2AX immunofluorescence staining. Scale bar, 20 μm. ( F ) ASC speck colocalization with AIM2, Caspase-1, Caspase-8, and RIPK1. Scale bars, 5 μm (overview) and 1 μm (enlarged). ( G ) Western blot analysis of necroptosis markers (RIPK1, p-RIPK1, MLKL, and p-MLKL) and PANoptosis-related proteins (AIM2 and ZBP1). ( H ) Western blot analysis of apoptosis executors (Caspase-8, Caspase-3, and cleaved forms). ( I ) Western blot analysis of pyroptosis markers (Caspase-1, GSDMD, and cleaved forms). ( J ) Cell viability after DDP + Zn 2+ combined with VX-765, Ac-DEVD-CHO, or Nec-1. ( K ) PANoptosis-related proteins in si AIM2 cells. ( L and M ) cGAS activity (L) and expression (M) under Zn 2+ treatment. ( N ) Violin plot of cGAS expression. ( O ) Western blot analysis of STING pathway (STING, p-STING, TBK1, p-TBK1, IRF3, and p-IRF3). ( P ) CIBERSORT analysis of immune cell infiltration. ( Q ) BMDC maturation (CD80 + CD86 + ) after different treatments. ( R ) Schematic of the DDP + Zn 2+ –induced ICD. Data in (C), (J), and (L) are mean ± SD. Statistical analysis for (C), (J), (L), (N), and (P) used a two-tailed unpaired Student’s t test. (R) was created in BioRender. Fei, G. (2026) https://BioRender.com/8ri399r . * P < 0.05.

Article Snippet: The pharmacological inhibitors VX-765, Ac-DEVD-CHO, and Nec-1 were purchased from MedChemExpress (USA).

Techniques: Control, Staining, Fluorescence, Microscopy, Flow Cytometry, Immunofluorescence, Western Blot, Analysis, Activity Assay, Expressing, Immune Cell, Two Tailed Test

Combined drug treatment induces reactive oxygen species–mediated DNA damage and apoptosis. (A-D) Fluorescence images and statistical graphs depicting the alterations in reactive oxygen species (ROS) levels in DLD-1 and HCT116 cells, following a 1-hour exposure to four distinct drug administration protocols. Scale bars=100 µm. (E, F) Immunofluorescence images of DNA damage signs (γ-H2AX and 53BP1) in HCT116 cells after treatment. Scale bars=5 µm. (G) Comparative analysis of cell survival rates in colorectal cancer cells following treatment with pathway-specific inhibitors. (H-J) Expression levels and statistical analysis of Bcl-2 and Bax under various treatment conditions: dimethyl sulfoxide (DMSO), lenvatinib (LEN), celastrol (CELA), and the combined group. DFO, deferoxamine mesylate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NEC, necrosulfonamide; Z-VAD, Z-VAD-FMK. Statistical significance was defined as * p < 0.05 and ** p < 0.01; ns, not significant.

Journal: Cancer Research and Treatment : Official Journal of Korean Cancer Association

Article Title: Synergistic Anticancer Effects of Lenvatinib and Celastrol via Reactive Oxygen Species–Mediated Endoplasmic Reticulum Stress and JNK Signaling in Colon Cancer Cells

doi: 10.4143/crt.2025.508

Figure Lengend Snippet: Combined drug treatment induces reactive oxygen species–mediated DNA damage and apoptosis. (A-D) Fluorescence images and statistical graphs depicting the alterations in reactive oxygen species (ROS) levels in DLD-1 and HCT116 cells, following a 1-hour exposure to four distinct drug administration protocols. Scale bars=100 µm. (E, F) Immunofluorescence images of DNA damage signs (γ-H2AX and 53BP1) in HCT116 cells after treatment. Scale bars=5 µm. (G) Comparative analysis of cell survival rates in colorectal cancer cells following treatment with pathway-specific inhibitors. (H-J) Expression levels and statistical analysis of Bcl-2 and Bax under various treatment conditions: dimethyl sulfoxide (DMSO), lenvatinib (LEN), celastrol (CELA), and the combined group. DFO, deferoxamine mesylate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NEC, necrosulfonamide; Z-VAD, Z-VAD-FMK. Statistical significance was defined as * p < 0.05 and ** p < 0.01; ns, not significant.

Article Snippet: Additionally, Z-VAD-FMK (Z-VAD), necrosulfonamide (NEC), SP600125 and hydroxychloroquine (HCQ) were purchased from Targetmol for use in the study.

Techniques: Fluorescence, Immunofluorescence, Analysis, Expressing

HBT triggers PC9-OR cells ferroptosis. A Fer-1 treatment attenuated 2.5 μΜ HBT-caused inhibition effect on PC9-OR cell proliferation. The PC9-OR cells were co-treated with apoptosis inhibitor Z-VAD-FMK, ferroptosis inhibitor Fer-1, autophagy inhibitor CQ or necroptosis inhibitor Nec-1 and HBT for 48 h, and then subjected for CCK-8 assay. B Fer-1 treatment weaken HBT-mediated PC9-OR cells death detected by Calcein-AM/PI staining assay. C HBT treatment induced intracellular ROS accumulation. D HBT treatment increased intracellular lipid peroxidation, as indicated by C11-BODIPY 581/591 staining assay. E HBT treatment increased intracellular Fe 2+ level. The PC9-OR cells were treated with various concentration of HBT for 12 h, and the Fe 2+ level were detected by flow cytometry. F , G HBT induced PC9-OR cells ferroptosis indicated by Western blotting assay. H HBT treatment induced mitochondrial morphology change. PC9-OR cells were treated with or without HBT for 24 h. And the subcellular organelle structure was observed using TME. All the data were presented as mean ± SD. n = 3. ** P < 0.01, *** P < 0.001 compared with the Vehicle group

Journal: Natural Products and Bioprospecting

Article Title: A fungal-derived benzothiazole derivative overcomes osimertinib resistance in NSCLC by targeting SCD1

doi: 10.1007/s13659-026-00645-9

Figure Lengend Snippet: HBT triggers PC9-OR cells ferroptosis. A Fer-1 treatment attenuated 2.5 μΜ HBT-caused inhibition effect on PC9-OR cell proliferation. The PC9-OR cells were co-treated with apoptosis inhibitor Z-VAD-FMK, ferroptosis inhibitor Fer-1, autophagy inhibitor CQ or necroptosis inhibitor Nec-1 and HBT for 48 h, and then subjected for CCK-8 assay. B Fer-1 treatment weaken HBT-mediated PC9-OR cells death detected by Calcein-AM/PI staining assay. C HBT treatment induced intracellular ROS accumulation. D HBT treatment increased intracellular lipid peroxidation, as indicated by C11-BODIPY 581/591 staining assay. E HBT treatment increased intracellular Fe 2+ level. The PC9-OR cells were treated with various concentration of HBT for 12 h, and the Fe 2+ level were detected by flow cytometry. F , G HBT induced PC9-OR cells ferroptosis indicated by Western blotting assay. H HBT treatment induced mitochondrial morphology change. PC9-OR cells were treated with or without HBT for 24 h. And the subcellular organelle structure was observed using TME. All the data were presented as mean ± SD. n = 3. ** P < 0.01, *** P < 0.001 compared with the Vehicle group

Article Snippet: osimertinib, Z-VAD-FMK, ferrostatin-1 (Fer-1), chloroquine (CQ) and necrostatin-1 (Nec-1) were products of TargetMol (Shanghai, China).

Techniques: Inhibition, CCK-8 Assay, Staining, Concentration Assay, Flow Cytometry, Western Blot